Product Value—GORE® ACUSEAL Vascular Graft

Clinical and economic value in dialysis access

Image of GORE ACUSEAL Vascular GraftThe GORE® ACUSEAL Vascular Graft provides economic value by reducing the overall incidence of central venous catheter (CVC) sepsis and related costs due to fewer CVC-dependent days.

By allowing earlier removal or avoidance of a CVC for hemodialysis patients, it can reduce fatal infections due to CVC complications1 and lower the costs of treating CVC sepsis by earlier removal of a CVC.1-3

Chart showing the average sepsis costs per patient

 

Photo of GORE ACUSEAL Vascular Graft

GORE® ACUSEAL Vascular Graft full product information

Learn more >

Three people discussing documents

Want more information?

Connect with one of our Corporate Account Directors to learn more about the value Gore can deliver to your healthcare institution.

 

Contact us >

The Future of Value Analysis

The Future of Value Analysis

A Handbook for Health Care Professionals

Read perspectives from value analysis professionals who share their thoughts regarding the importance of effective collaboration, paradigm shifts with determining value, and the critical focus on the future of healthcare.

 

Download the handbook >

To learn more, contact us.

INDICATIONS FOR USE: GORE® ACUSEAL Vascular Grafts are intended for use as a vascular prosthesis in patients requiring vascular access.

CONTRAINDICATIONS: A. DO NOT use the GORE® ACUSEAL Vascular Graft in patients with known hypersensitivity to heparin, including those patients who have had a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II. B. DO NOT use GORE® ACUSEAL Vascular Grafts as a patch. If cut and used as a patch, GORE® ACUSEAL Vascular Grafts may lack adequate transverse strength.

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

eIFU Symbol

* Cost savings of $3,169 per patient with avoidance of 18.5 CVC-dependent days.

  1. GORE® ACUSEAL Vascular Graft [Instructions for Use]. Flagstaff, AZ:W.L. Gore & Associates, Inc;2016.MD141588.
  2. Ravani P, Palmer SC, Oliver MJ, et al. Associations between hemodialysis access type and clinical outcomes: a systematic review. Journal of the American Society of Nephrology 2013;24(3):465-473.
  3. Mohr BA, Trovillion PJ, Economic value of preventing central venous catheter sepsis infections with early cannulation arteriovenous grafts (ECAVGS) compared to non-ecavgs. Presented at the ISPOR 20th Annual International Meeting; May 16-20; Philadelphia, PA. Value in Health 2015;18(3):A42.PMD26.

21360950-EN

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.